Neoplasms

All Conditions

Digestive System Diseases

Carcinoma

Carcinoma, Hepatocellular

Liver Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Adenocarcinoma

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

All Drugs and Chemicals

Antineoplastic Agents

Hematinics

Immunomodulating Agents

Chlorotrianisene

Liver Extracts

IKC (Immune Killer Cells) and TACE(Transcatheter Arterial Chemoembolization)

TACE (Transcatheter Arterial Chemoembolization)

IKC (Immune Killer Cells)

Executive Assistant

Chung-Bao Hsieh, MD

The purpose of this study is to evaluate the efficacy of ex vivo expanded autologous immune killer cells in treating hepatocellular carcinoma patients in：

1. Reduction of tumor size
2. Reducing the relapse rate: Reducing the frequency of TACE treatment by IKC injections.

This is a phase II/III clinical study. Blood is drawn from the patient and brought to our laboratory for isolation of immune cells. These immune cells are then proliferated over a two week period and used to produce the patented product IKC (Immune Killer Cells). The IKC will then infused back into the patient to treat the cancer. Each patient will receive a total of twelve infusions.

60 patients are anticipated to be recruited. This is a double-arm study, the experimental group will receive IKC treatment along with TACE treatment. The control group will receive only TACE treatment. 30 patients will be randomized into each arm.

Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

A Phase II/III Clinical Trial With Ex Vivo Expanded Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy

Evaluate the efficacy of autologous immune killer cells using Response Evaluation Criteria in Solid Tumors (RECIST) by recording net changes of tumor sizes

The length of time during and after the treatment of a disease, that a patient lives with the disease but it does not get worse

Evaluate the efficacy and safety of in vitro proliferating autoimmune killer cells as adjuvant therapy for the treatment of liver cancer patients and promote anti-cancer immune responses

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy	NCT03592706	HepatoCellular ... Liver Cancer	IKC (Immune Kil... TACE (Transcath...	20 Years - 79 Years	Ivy Life Sciences, Co., Ltd
Autologous Immune Killer Cells to Treat Liver Cancer Patients as an Adjunct Therapy	NCT03592706	HepatoCellular ... Liver Cancer	IKC (Immune Kil... TACE (Transcath...	20 Years - 79 Years	Ivy Life Sciences, Co., Ltd

Spots Global Cancer Trial Database for ikc (immune killer cells)